Clinical trials: Cirrhosis, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Cirrhosis
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Hepatic Encephalopathy, Liver Cirrhosis
Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy
The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults.
- Conditions
- Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
- Trial name
- NCT07553858
- Testing
- Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old living with obesity and have: a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and moderate or advanced…
- Trial name
- NCT06632444
- Testing
- Survodutide
- Where
- 532 sites in United States, Argentina and 35 more
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim
Intrahepatic Cholangiocarcinoma (Icc)
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
- Trial name
- NCT06721286
- Testing
- Teripalimab, Gemcitabine + Cisplatin, Surgery
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Overt Hepatic Encephalopathy
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but…
- Trial name
- NCT06483737
- Testing
- Human albumin infusion at a modified dosage, Human albumin infusion at a routine dosage, Lactulose
- Where
- China
- Volunteers
- 174 people
- Sponsor
- General Hospital of Shenyang Military Region
Cirrhosis, Portal Hypertension
4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis
PORTAL-4D is a prospective, interventional, non-randomized, parallel-group diagnostic study conducted at Pitié-Salpêtrière Hospital (Paris, France).
- Trial name
- PORTAL-4D (NCT07554183)
- Testing
- 4D-Flow Liver and heart MRI with Gadolinium injection, Samples Without DNA
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Decompensated Cirrhosis
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
Three sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg).
- Trial name
- HCL001 (NCT07488546)
- Testing
- Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Huicun Medical Technology Co., Ltd.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Intrahepatic Cholangiocarcinoma (Icc)
A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)
- Trial name
- ACADEMY (NCT06925516)
- Testing
- Apatinib and Adebrelimab in Combination With chemotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Portal Hypertension, Gastric Varices Bleeding
Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis
The prevalence of gastric varices is approximately 20%. It is important to note that gastric varices tend to bleed more severely, have a higher morbidity and mortality rate, and have a 35% to 90% risk of rebleeding after the…
- Conditions
- Portal Hypertension, Gastric Varices Bleeding, Portosystemic Shunt
- Trial name
- NCT06122792
- Testing
- preemptive TIPS, standard second prophylaxis
- Volunteers
- 144 people
- Sponsor
- West China Hospital
Hepatitis B, Cirrhosis, Liver
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
- Conditions
- Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
- Trial name
- NCT04588077
- Testing
- Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mercy Medical Center
Cirrhosis Liver
A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis
A single-arm, open-label, dose-escalation phase I clinical trial to evaluate the safety, tolerability, and preliminary efficacy of CUD005 injection in patients with liver cirrhosis
- Trial name
- NCT06671275
- Testing
- Cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Fragility, Cirrhosis
Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)
Cirrhosis is a major public health issue responsible for about 15000 deaths each year. Liver transplantation (LT) remains the only curative treatment for decompensated cirrhosis.
- Conditions
- Fragility, Cirrhosis, Hepatic Transplantation, Undernutrition
- Trial name
- LFI-PATH (NCT06911619)
- Testing
- Dietary management, No dietary management
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Hospices Civils de Lyon
Liver Cirrhosis
Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment
This study Phase 1 clinical trial aimed to evaluate the safety and preliminary efficacy of intravenously administered extracellular vesicles derived from umbilical cord mesenchymal stem cells (UC-MSC-EVs; VinEV-3) in patients…
- Trial name
- NCT07472270
- Testing
- Umbilical cord mesenchymal stem cell-derived extracellular vesicles
- Where
- Vietnam
- Volunteers
- 12 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding
Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients
The goal of this randomized controlled clinical trial is to evaluate the efficacy of Tranexamic acid and vitamin K injection versus placebo in control of upper gastrointestinal bleeding (UGIB) in Egyptian cirrhotic patients.
- Conditions
- Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis
- Trial name
- NCT06881628
- Testing
- Tranexamic Acid and vitamin K
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Tanta University
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Liver Cirrhosis
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
Acute upper gastrointestinal bleeding (AUGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension.
- Trial name
- NCT07252401
- Testing
- 2-4 mg of terlipressin, 3 mg of somatostatin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- General Hospital of Shenyang Military Region
Cirrhosis
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease.
- Trial name
- NCT07652203
- Testing
- conventional therapy, propranolol
- Where
- China
- Volunteers
- 466 people
- Sponsor
- General Hospital of Shenyang Military Region
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University